A Phase Ib Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (VCDI) in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplantation

被引：1
作者：
Ocio, Enrique M.
Bringhen, Sara
Oliva, Stefania
Rodriguez-Otero, Paula
Kanagavel, Dheepak
Oprea, Corina
Wei, Vivian
Doroumian, Severine
Martinez-Lopez, Joaquin
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3160
引用
收藏
页数：3
相关论文
共 50 条
[21]   Canadian Retrospective Multicentric Study Comparing the Combination of Bortezomib, Cyclophosphamide and Dexamethasone (Cybord) Versus Bortezomib, Thalidomide and Dexamethasone (VTD) Versus Bortezomib and Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma Eligible for Autologous Hematopoietic Stem Cell Transplantation (HCT) [J].
Yamga, Eric ;
Leblanc, Richard ;
Boudreault, Jean-Samuel .
BLOOD, 2018, 132
[22]   Comparison of lenalidomide, bortezomib, dexamethasone vs bortezomib, cyclophosphamide, dexamethasone as an induction regimen in newly diagnosed myeloma patients eligible for intensive chemotherapy [J].
Van de Wyngaert, Zoe ;
Malard, Florent ;
Marjanovitch, Zora ;
Alsuliman, Tamim ;
Ikhlef, Souhila ;
Mohty, Mohamad .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 :S137-S137
[23]   Dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed multiple myeloma [J].
Kropff, Martin ;
Liebisch, Peter ;
Wand, Hannes ;
Weisel, Katja ;
Gann, Claudia-Nanette ;
Knop, Stefan ;
Einsele, Hermann .
BLOOD, 2007, 110 (11) :1053A-1053A
[24]   Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study [J].
Yimer, Habte ;
Melear, Ason ;
Faber, Edward ;
Bensinger, William, I ;
Burke, John M. ;
Narang, Mohit ;
Stevens, Don ;
Gunawardena, Sriya ;
Lutska, Yana ;
Qi, Keqin ;
Ukropec, Jon ;
Qi, Ming ;
Lin, Thomas S. ;
Rifkin, Robert M. .
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (03) :492-502
[25]   Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial [J].
O'Donnell, Elizabeth ;
Mo, Clifton ;
Yee, Andrew J. ;
Nadeem, Omar ;
Laubach, Jacob ;
Rosenblatt, Jacalyn ;
Munshi, Nikhil ;
Midha, Shonali ;
Cirstea, Diana ;
Chrysafi, Pavlina ;
Horick, Nora ;
Richardson, Paul G. ;
Raje, Noopur .
LANCET HAEMATOLOGY, 2024, 11 (06) :e415-e424
[26]   Updates from a phase Ib study of isatuximab (Isa), bortezomib (V) and dexamethasone (D) plus cyclophosphamide (C) or lenalidomide (R) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM). [J].
Ocio, Enrique M. ;
Rodriguez Otero, Paula ;
Bringhen, Sara ;
Oliva, Stefania ;
Nogai, Axel ;
Attal, Michel ;
Moreau, Philippe ;
Martinez-Lopez, Joaquin ;
Le Roux, Nadia ;
Mace, Sandrine ;
Rouchon, Marie-Claude ;
Wang, Qiuyan ;
Mateos, Maria-Victoria .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[27]   Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial [J].
Muranushi, Hiroyuki ;
Kanda, Junya ;
Kobayashi, Masayuki ;
Maeda, Takeshi ;
Kitano, Toshiyuki ;
Tsuji, Masaaki ;
Ueda, Yasunori ;
Ishikawa, Takayuki ;
Nohgawa, Masaharu ;
Watanabe, Mitsumasa ;
Imada, Kazunori ;
Moriguchi, Toshinori ;
Itoh, Mitsuru ;
Ohno, Hitoshi ;
Yonezawa, Akihito ;
Hirata, Hirokazu ;
Arima, Nobuyoshi ;
Asagoe, Kohsuke ;
Anzai, Naoyuki ;
Nagata, Kayoko ;
Yasuno, Shinji ;
Kuwabara, Yoshihiro ;
Kitao, Hiromi ;
Kim, Ihhwa ;
Kawagishi, Kiyomi ;
Ueshima, Kenji ;
Tominari, Shinjiro ;
Nakayama, Takeo ;
Yamashita, Kouhei ;
Takaori-Kondo, Akifumi .
HEMATOLOGY, 2022, 27 (01) :239-248
[28]   A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma [J].
O'Donnell, Elizabeth K. ;
Mo, Clifton C. ;
Yee, Andrew J. ;
Nadeem, Omar ;
Branagan, Andrew R. ;
Laubach, Jacob P. ;
Gammon, Marilyn T. ;
Lively, Kathleen J. ;
Packer, Lisette ;
Harrington, Cynthia C. ;
Agyemang, Emerentia ;
Spillane, Kerry ;
LaStofka, Brenton ;
Rosenblatt, Jacalyn ;
Raje, Noopur S. ;
Richardson, Paul G. .
BLOOD, 2021, 138
[29]   Isatuximab Plus Lenalidomide and Dexamethasone With Bortezomib Versus Isatuximab Plus Lenalidomide and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma: The Benefit Study [J].
Leleu, Xavier ;
Hulin, Cyrille ;
Lambert, Jerome ;
Bobin, Arthur ;
Perrot, Aurore ;
Manier, Salomon ;
Jaccard, Arnaud ;
Montes, Lydia ;
Karlin, Lionel ;
Godmer, Pascal ;
Chalopin, Thomas ;
Slama, Borhane ;
Chretien, Marie Lorraine ;
Laribi, Karim ;
Dingremont, Claire ;
Roul, Christophe ;
Mariette, Clara ;
Rigaudeau, Sophie ;
Macro, Margaret ;
Mohty, Mohamad ;
Touzeau, Cyrille ;
Moreau, Philippe ;
Avet-Loiseau, Herve ;
Corre, Jill ;
Facon, Thierry .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 :S33-S33
[30]   Pomalidomide, Bortezomib, and Dexamethasone Combination Chemotherapy for Newly Diagnosed Multiple Myeloma: Pomace Phase II Study [J].
Saj, Fen ;
Ganesan, Prasanth ;
Kayal, Smita ;
Dubashi, Biswajit .
BLOOD, 2022, 140 :12612-12612
12345